Emmanuel Griessinger
Overview
Explore the profile of Emmanuel Griessinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boet E, Saland E, Skuli S, Griessinger E, Sarry J
C R Biol
. 2024 Aug;
347:59-75.
PMID: 39171610
A large body of literature highlights the importance of energy metabolism in the response of haematological malignancies to therapy. In this review, we are particularly interested in acute myeloid leukaemia,...
2.
Kleftogiannis D, Gavasso S, Tislevoll B, van der Meer N, Motzfeldt I, Hellesoy M, et al.
iScience
. 2024 Jul;
27(7):110261.
PMID: 39021803
Mass cytometry by time-of-flight (CyTOF) is an emerging technology allowing for in-depth characterization of cellular heterogeneity in cancer and other diseases. Unfortunately, high-dimensional analyses of CyTOF data remain quite demanding....
3.
Griessinger E, Pereira-Martins D, Nebout M, Bosc C, Saland E, Boet E, et al.
Cancer Res
. 2023 Jun;
83(15):2461-2470.
PMID: 37272750
Significance: Mitochondrial metabolism fueled by FAO alters the membrane composition and introduces membrane fragility upon cold exposure in OxPhos-driven AML and in LSCs. See related commentary by Jones, p. 2441.
4.
Lima K, Pereira-Martins D, de Miranda L, Coelho-Silva J, da Silva Leandro G, Weinhauser I, et al.
Blood Cancer J
. 2022 Nov;
12(11):151.
PMID: 36347832
The treatment of acute leukemia is challenging because of the genetic heterogeneity between and within patients. Leukemic stem cells (LSCs) are relatively drug-resistant and frequently relapse. Their plasticity and capacity...
5.
Griessinger E, Andreeff M
Haematologica
. 2018 Jun;
103(6):921-923.
PMID: 29866886
No abstract available.
6.
Rodriguez A, Nakhle J, Griessinger E, Vignais M
Cell Cycle
. 2018 Mar;
17(6):712-721.
PMID: 29582715
Mitochondria are crucial organelles that not only regulate the energy metabolism, but also the survival and fate of eukaryotic cells. Mitochondria were recently discovered to be able to translocate from...
7.
Bertoli S, Picard M, Berard E, Griessinger E, Larrue C, Mouchel P, et al.
Haematologica
. 2018 Mar;
103(6):988-998.
PMID: 29519869
Patients with acute myeloid leukemia and a high white blood cell count are at increased risk of early death and relapse. Because mediators of inflammation contribute to leukostasis and chemoresistance,...
8.
Griessinger E, Vargaftig J, Horswell S, Taussig D, Gribben J, Bonnet D
Exp Hematol
. 2017 Dec;
59:66-71.e4.
PMID: 29253573
Xenograft assay allows functional analysis of leukemia-initiating cells of acute myeloid leukemia primary samples. However, 40% of samples derived from patients with better outcomes fail to engraft in immunodeficient mouse...
9.
Griessinger E, Moschoi R, Biondani G, Peyron J
Trends Cancer
. 2017 Dec;
3(12):828-839.
PMID: 29198439
The bone marrow microenvironment (BMME) is a complex ecosystem that instructs and protects hematopoietic stem cells (HSCs) and their malignant counterparts, the leukemia-initiating cells (LICs). Within the physical and functional...
10.
Farge T, Saland E, De Toni F, Aroua N, Hosseini M, Perry R, et al.
Cancer Discov
. 2017 Apr;
7(7):716-735.
PMID: 28416471
Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC). To validate this hypothesis , we developed a clinically relevant chemotherapeutic...